Finance

Lists
Outlook: 76.9% bullish·0.0% bearish
Go to analysis
ADPT:NASDAQ
Adaptive Biotechnologies Corp
$29.04
-1.49%
(-0.44) 1D
$29.04
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ADPT...
Open
$29.69
High
$29.78
Low
$28.38
Mkt. cap
4.70B
Avg. vol.
2.15M
Volume
2.06M
52-wk high
$32.13
52-wk low
$12.00
EPS
-$0.45
Beta
2.18
Shares outstanding
161.88M
No. of employees
624
Open
$29.69
High
$29.78
Low
$28.38
Mkt. cap
4.70B
Avg. vol.
2.15M
Volume
2.06M
52-wk high
$32.13
52-wk low
$12.00
EPS
-$0.45
Beta
2.18
Shares outstanding
161.88M
No. of employees
624
News stories
From web sources and news partners
About Adaptive Biotechnologies Corp
CEOChad Robins
Employees624
Founded2009
HeadquartersSeattle, Washington, United States
SectorHealth Care
Industry-
Websiteadaptivebiotech.com
Analyst ratings
Based on 8 analysts giving stock ratings to ADPT in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for ADPT in the last 3 months.
Highest
Current $29.04
$35.00 (+20.52%)
Average
$33.43 (+15.12%)
Lowest
$27.00 (-7.02%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Westenberg
Piper Sandler
Buy
Reiterated
$35.00
+20.5%
11/10/2026
Subbu Nambi
Guggenheim
Buy
Reiterated
$34.00
+17.1%
11/10/2026
Casey Woodring
J.P. Morgan
Buy
Reiterated
$35.00
+20.5%
11/09/2026
Mark Massaro
BTIG
Buy
Reiterated
$34.00
+17.1%
11/05/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
$34.00
+17.1%
11/05/2026
Kallum Titchmarsh
Morgan Stanley
Hold
Maintained
$27.00
-7%
10/13/2026
Evie Koslosky
Goldman Sachs
Buy
Initiated
$35.00
+20.5%
09/29/2026
William Bonello
Craig-Hallum
Buy
Maintained
-
-
09/17/2026
Sebastian Sandler
J.P. Morgan
Buy
Maintained
$27.00
-7%
07/30/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/30/2026
Andrew Brackmann
William Blair
Buy
Reiterated
-
-
06/16/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
$0.02 / -$0.10
+120.31%beat
Revenue / Est. (USD)
83.90M / 71.60M
+17.18%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
71.68M
70.87M
71.55M
83.90M
Cost of goods sold
39.99M
42.33M
39.32M
38.57M
Cost of revenue
39.99M
42.33M
39.32M
38.57M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
44.04M
47.33M
47.58M
45.36M
Operating expense
44.47M
47.75M
48.00M
45.79M
Total operating expenses
84.45M
90.08M
87.32M
84.36M
Operating income
-12.77M
-19.21M
-15.77M
-457.00K
Other non operating income
-
-
-
-
EBT including unusual items
-13.58M
-20.02M
-39.94M
2.81M
EBT excluding unusual items
-13.87M
-20.15M
-16.21M
2.81M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-13.58M
-20.03M
-39.79M
2.88M
Net profit margin
-18.94%
-28.27%
-55.61%
3.43%
Earnings per share
-0.09
-0.13
-0.25
0.02
Interest and investment income
1.86M
1.94M
2.26M
3.77M
Interest expense
-2.95M
-2.89M
-2.69M
-503.00K
Net interest expenses
-1.09M
-945.00K
-438.00K
3.26M
Depreciation and amortization charges
-
-
-
-
EBITDA
-8.58M
-15.37M
-12.08M
3.15M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps